$OBMP is in an interesting phase of its existence.
Post# of 47038
(Total Views: 269)
Posted On: 01/19/2017 5:04:19 PM
$OBMP is in an interesting phase of its existence. The company just solidified its sense of credibility in the space with a recent announcement of a productive meeting with top staffing scientists at the host hospital of the Company’s upcoming Phase 2 trial of ProscaVax for prostate cancer. That represents the first brick in the wall toward some seriously valuable IP.
The company is trading right now at a market cap of just $7.9M, making it practically free for the likes of Eli Lilly and Co (NYSE:LLY), Nymox Pharmaceutical Corporation (NASDAQ:NYMX), or Pfizer Inc. (NYSE
FE), all of which have been hot on the trail of IP geared toward the prostate cancer market. A price tag under $100M for a viable play into that $7 billion prostate cancer market is a fine starting idea to a conversation among any of these players.
OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is a clinical stage biopharmaceutical company that develops cancer immunotherapy products. The company has proprietary rights to a breast and prostate patent vaccine; and a process for the growth of cancer cells and targeted chemotherapies. Its lead product is ProscaVax that is in the planning stage of a Phase II clinical trial for the treatment of prostate cancer. https://wallstreetpr.com/oncbiomune-pharmaceu...date-37725
The company is trading right now at a market cap of just $7.9M, making it practically free for the likes of Eli Lilly and Co (NYSE:LLY), Nymox Pharmaceutical Corporation (NASDAQ:NYMX), or Pfizer Inc. (NYSE
FE), all of which have been hot on the trail of IP geared toward the prostate cancer market. A price tag under $100M for a viable play into that $7 billion prostate cancer market is a fine starting idea to a conversation among any of these players. OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is a clinical stage biopharmaceutical company that develops cancer immunotherapy products. The company has proprietary rights to a breast and prostate patent vaccine; and a process for the growth of cancer cells and targeted chemotherapies. Its lead product is ProscaVax that is in the planning stage of a Phase II clinical trial for the treatment of prostate cancer. https://wallstreetpr.com/oncbiomune-pharmaceu...date-37725
(0)
(0)Scroll down for more posts ▼